Oxra‑S 10/100 mg (Dapagliflozin/Sitagliptin) – Product Overview

Oxra‑S 10/100 mg is a prescription oral antidiabetic tablet manufactured by Sun Pharmaceutical Industries Ltd. It combines two pharmacologically distinct agents, dapagliflozin 10 mg and sitagliptin 100 mg, into a single fixed‑dose formulation. The product is indicated for adults with type 2 diabetes mellitus who require additional glycemic control beyond diet and exercise. Each strip contains 15 tablets, and the medication is marketed in pack sizes of 60, 120, or 240 tablets to accommodate long‑term therapy. The fixed‑dose approach simplifies the medication regimen, improves adherence, and provides consistent exposure of both active ingredients.

What is Oxra‑S 10/100 mg?

Oxra‑S 10/100 mg represents a fixed‑dose combination that delivers dapagliflozin, an SGLT‑2 inhibitor, alongside sitagliptin, a DPP‑4 inhibitor, in a single tablet. Dapagliflozin blocks the SGLT‑2 transporter in the renal proximal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. Sitagliptin inhibits DPP‑4, preserving incretin hormones that enhance insulin secretion and suppress glucagon release in a glucose‑dependent manner. Together they address both basal and post‑prandial glucose excursions, offering a comprehensive approach to glycemic management. The product is identified by the strength “10 mg/100 mg” and is exclusively marketed by Sun Pharmaceutical Industries Ltd. It is not indicated for type 1 diabetes or for use as monotherapy in patients who have not previously used a glucose‑lowering agent.

Uses and Benefits

The therapeutic uses of Oxra‑S extend beyond simple glucose reduction. Clinical trials have shown modest reductions in HbA1c of 0.5% to 1.0% when used alone, with greater improvements when combined with metformin. The SGLT‑2 component provides cardiovascular and renal protection, lowering the risk of heart‑failure hospitalization and slowing progression of chronic kidney disease in patients with existing disease. The DPP‑4 component is weight‑neutral and carries a low risk of hypoglycemia when used as monotherapy. Additionally, the diuretic effect of dapagliflozin can lead to modest weight loss. These attributes make Oxra‑S a valuable option for individuals who require dual‑mechanism therapy without the complexity of multiple pills.

How It Works

Dapagliflozin inhibits the SGLT‑2 transporter, causing increased urinary glucose elimination independent of insulin pathways. This action also reduces intravascular volume, contributing to modest blood‑pressure lowering. Sitagliptin blocks DPP‑4, preserving incretin hormones such as GLP‑1 and GIP, which enhance glucose‑dependent insulin secretion and suppress glucagon release. Because the incretin‑enhancing effect is glucose‑dependent, the risk of hypoglycemia remains low when sitagliptin is used without insulin or sulfonylureas. The combined effect improves fasting and post‑prandial glucose concentrations, modestly improves lipid profiles, and may confer cardioprotective benefits through the SGLT‑2 inhibition pathway.

Dosage Guidelines

The recommended adult dosage of Oxra‑S is one tablet taken orally once daily, with or without food. The tablet delivers 10 mg of dapagliflozin and 100 mg of sitagliptin in a single dose. No dose adjustment is required for mild hepatic impairment, but caution is advised in severe liver disease. For patients with an estimated glomerular filtration rate (eGFR) of 45–59 mL/min/1.73 m², the medication can be used at the standard dose, while an eGFR below 45 mL/min/1.73 m² constitutes a contraindication. If a dose is missed, it should be taken as soon as remembered unless the next scheduled dose is less than 12 hours away; in that case, the missed dose should be skipped. Routine monitoring of renal function, liver enzymes, and fasting glucose is recommended at intervals determined by the prescribing clinician.

Side Effects

Most adverse events associated with Oxra‑S are mild, but some require medical attention. Common side effects include urinary tract infections, genital mycotic infections, increased urinary frequency, and mild dehydration. Less common but serious events comprise acute kidney injury, euglycemic ketoacidosis, and hypersensitivity reactions such as rash or angioedema. When Oxra‑S is used together with insulin or sulfonylureas, the potential for hypoglycemia increases, necessitating dose adjustments of the accompanying agent. Patients should promptly report persistent genital discomfort, severe abdominal pain, or signs of infection to their healthcare provider.

Warnings and Precautions

Oxra‑S is contraindicated in patients with a known hypersensitivity to dapagliflozin, sitagliptin, or any component of the formulation. It is not indicated for type 1 diabetes or for individuals with a history of diabetic ketoacidosis. Caution is advised in patients with a history of pancreatitis, severe renal impairment, or hepatic disease, as these conditions may increase the risk of adverse events. The medication should be discontinued before surgical procedures that could impair renal perfusion. Pregnant women should avoid Oxra‑S unless the benefits clearly outweigh the risks, and breastfeeding is discouraged due to potential drug excretion in milk. Concomitant use of other glucose‑lowering agents should be reviewed to avoid additive hypoglycemic effects, and renal function should be reassessed periodically.

Frequently Asked Questions

• Q1: Can Oxra‑S be taken with other diabetes medications?

  Yes, it may be used as monotherapy or in combination with metformin, insulin, or sulfonylureas. When combined with insulin or sulfonylureas, dose adjustment of the latter may be necessary to reduce the risk of hypoglycemia.

• Q2: How long does it take to see a reduction in HbA1c?

  Clinical studies demonstrate a modest decrease in HbA1c after approximately 12 weeks of treatment, with additional improvements possible after 24–26 weeks of continuous therapy.

• Q3: Is Oxra‑S safe for patients with kidney disease?

  The medication is contraindicated in patients with an eGFR below 45 mL/min/1.73 m². For those with an eGFR of 45–59 mL/min/1.73 m², use is allowed but requires close monitoring of renal function.

• Q4: Does Oxra‑S cause weight loss?

  The SGLT‑2 component may lead to mild weight loss due to urinary glucose excretion, while the DPP‑4 component is generally weight‑neutral. Overall, patients may experience modest reductions in body weight over time.

• Q5: Where can I find more detailed information about Oxra‑S?

  Comprehensive prescribing information is available on the U.S. Food and Drug Administration website, as well as on Drugs.com and MedlinePlus. Additional scientific context can be found through the National Institutes of Health and the Wikipedia entry on dapagliflozin.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)